Parallel Fluidics Builds Post-Conference Pipeline With LNP Screening Array Push

Parallel Fluidics, a microfluidics and lab automation company, focused this week on commercial outreach for its LNP Screening Array following an active presence at the SLAS 2026 conference. The firm emphasized that the array enables lipid nanoparticle screening directly on existing liquid-handling systems, minimizing the need for new capital equipment and lowering adoption barriers.

Across multiple LinkedIn updates, the company reported strong engagement with conference attendees, including discussions about customer workflows and plans to schedule follow-up demonstrations. Parallel Fluidics is also directing potential users who did not attend SLAS to request a Starter Array, aiming to extend its sales funnel beyond the event and convert interest into pilot evaluations.

The LNP Screening Array is positioned as a configurable microfluidic platform that supports staggered herringbone, flow focusing, and T-junction mixing geometries to tune particle size and polydispersity index. By automating these mixer configurations on liquid-handler decks, the solution targets higher-throughput, more reproducible LNP formulation workflows for applications such as mRNA therapeutics and nanoparticle-based drug delivery.

From an investment perspective, the week’s developments underscore an early-stage but deliberate push to build a pipeline of prospective users in the lab automation and drug-delivery R&D markets. While no quantitative sales metrics were disclosed, increased visibility at a specialized industry forum like SLAS and the emphasis on demos and starter kits may support future revenue opportunities and strengthen the company’s positioning in the emerging LNP and microfluidics ecosystem.

Overall, it was a week centered on conference-driven lead generation and product positioning, as Parallel Fluidics worked to translate technical interest in its LNP Screening Array into broader market traction and longer-term commercial relationships.